E-mail: klhem@amg.gda.pl
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY
- Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials
- Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy
- CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry
- Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab
- Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib
- EFFICIENT HDAC INHIBITION AND TARC REDUCTION IN PATIENTS WITH REFRACTORY HODGKIN LYMPHOMA TREATED WITH RESMINOSTAT - PK/PD DATA FROM THE PHASE II SAPHIRE STUDY
- EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies
- Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma
- Incidence of CML in Europe - a Comparison of 19 European Countries with US SEER Data
- Long-Term Experience with Anagrelide (Thromboreductin®) In the Treatment of Essential Thrombocythemia: Data from an International Registry
- Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.
- Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry
- Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)
- Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study
- The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry
- THE EUTOS POPULATION BASED REGISTRY – INCIDENCES OF CML ACROSS EUROPE
- THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES
- Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry
- TREATMENT WITH NILOTINIB IN EARLY CHRONIC PHASE CML–FIRST RESULTS FROM THE ENEST1ST SUB STUDY CAMN107EIC01
- VALIDATION OF THE EUTOS SCORE FOR PREDICTION OF COMPLETE CYTOGENETIC RESPONSE AND PROGRESSION FREE SURVIVAL: APPLICATION TO INDEPENDENT DATA FROM THE EUTOS REGISTRY AND REVIEW OF PUBLICATIONS
